Vaccine for HPV: A Vital Tool for Cancer Prevention
Imagine if we had a vaccine for serious cancers like breast cancer or lung cancer. Well, when it comes to cervical cancer, there’s actually a vaccine available. Every year, around 48,000 new cases of cancers tied to the human papillomavirus (HPV) are reported in the U.S., according to the Centers for Disease Control and Prevention (CDC).
Nevertheless, there’s surprisingly low awareness about HPV and its vaccine. A new study shows that over a third of American adults don’t even know about HPV or the vaccine designed to counter it. Some states have even higher percentages of unawareness, which is a bit concerning.
This lack of awareness is why educating the public about HPV, its associated cancers, and the effectiveness of the HPV vaccine is so crucial.
To shed some light on these issues, I chatted with Dr. Leana Wen, a wellness expert with a background in emergency medicine. She’s also a mom and has a pretty impressive resume.
What is HPV, and what cancers are related to it?
Dr. Wen explains that HPV is a virus with over 100 different types. Most infections don’t lead to cancer, but certain types are linked to cancers like cervical, vaginal, vulvar, penile, and anal cancers. Interestingly, some oral and throat cancers can also be associated with this virus.
Cervical cancer, which is the most common among HPV-related cancers, sees about 13,000 new cases annually in the U.S., leading to roughly 4,000 deaths. But that statistic only scratches the surface—there’s a broader spectrum of around 48,000 new cancers tied to HPV each year, making education on this virus essential.
Are there symptoms for those with HPV?
Wen points out that while some HPV strains can cause warts, most high-risk types do not present any symptoms during the initial infection. However, symptoms may surface later if precancerous or cancerous cells develop. The National Cancer Institute emphasizes that HPV infections are exceedingly common; almost all sexually active individuals will become infected within a few years. Roughly half of these infections involve high-risk HPV.
Typically, the body clears most infections naturally without any resulting cancers. However, certain high-risk strains can linger and potentially lead to cancer years later.
How is HPV transmitted?
According to Wen, the primary method of HPV transmission is through sexual intercourse, though close skin-to-skin contact can also spread the virus. The significance of understanding how prevalent HPV is cannot be overstated—it’s important to know that those with high-risk HPV often don’t show any symptoms. While condoms can help reduce the risk, they don’t provide complete protection against HPV, which is why vaccination is essential for preventative measures.
What’s the effectiveness of the HPV vaccine?
The HPV vaccine boasts an efficacy that’s close to 100% for preventing cervical cancer in women, as reported by the CDC. It’s also effective in preventing anal cancer in men who have sex with men and reduces the likelihood of developing genital warts.
When should the vaccine be administered?
The CDC advises that preteens receive their first vaccine dose around ages 11 or 12, although it can be given as early as age 9. For those aged 9 to 14, a two-dose series is recommended, while those beginning vaccination between the ages of 15 and 45, along with immunocompromised individuals, should receive a three-dose series.
Concerns about encouraging premature sexual activity
Some parents worry that receiving the vaccine might prompt their children to engage in sexual activity earlier. Wen counters this concern by referencing a substantial study that found no increase in risky sexual behavior among vaccinated individuals. Other research corroborates that HPV vaccination has no connection to the timing of first sexual encounters or the number of partners.
Given how prevalent high-risk HPV is, having a vaccine that effectively protects against related cancers is incredibly valuable. It’s not about encouraging any specific behavior; it’s about providing protection in case of future exposure.
Final thoughts
Wen emphasizes that public awareness of both HPV and its vaccine is alarmingly low. In some states, over 40% of adults are unaware of HPV, while in others, 60% don’t realize that it can lead to oral cancers. There’s a pressing need to raise awareness among adolescents, parents, and healthcare professionals alike.
